| 5,268 | 25 | 108 |
| 下载次数 | 被引频次 | 阅读次数 |
灭活疫苗使用历史悠久,作为传统和经典的疫苗研发路线,生产工艺简单成熟,免疫原性稳定,使用较为安全。为应对2019冠状病毒病全球大流行,目前至少10种新型冠状病毒灭活疫苗进入临床试验或处于临床前研究。本文综述了灭活疫苗的基本工艺技术要点,对严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒灭活疫苗研发经验,以及新型冠状病毒灭活疫苗研发进展、预期问题和挑战进行了总结。
Abstract：Inactivated vaccines have been used for decades and are considered a traditional, classic type of vaccine. They are characterized by simple and mature production processes, stable immunogenicity, and good safety profiles. To date, there are ten inactivated novel coronavirus vaccine candidates for coronavirus disease 2019(COVID-19) that are in preclinical or clinical stages of development. In this article, we review production processes of inactivated vaccines, clinical trials of inactivated vaccines for severe acute respiratory syndrome coronavirus(SARS) and Middle East respiratory syndrome coronavirus(MERS), and progress on research and development of inactivated COVID-19 vaccines. We identify potential problems and challenges for developing inactivated COVID-19 vaccines.
[1]国家食品药品监督管理局.预防用疫苗临床前研究技术指导原则[S].2010-04-12.
[2]GAO Q,BAO L,MAO H,et al.Development of an inactivated vaccine candidate for SARS-CoV-2[J].Science,2020,369(6499):77-81.
[3]吴冰洁,陆柔剑,谭文杰.病毒分离培养新技术及其应用[J].中国病毒病杂志,2017,7(2):154-158.WU Bingjie,LU Roujian,TAN Wenjie.Development and application of novel techniques for viral isolation and culture[J].Chinese Journal of Viral Diseases,201 7,7(2):154-1 58.
[4]KAMARAJ G,LAKSHMI NARASU M,SRINIVASAN VA.Validation of beta propiolactone(BPL)as an inactivate for infectious bovine rhinotracheitis(IBR)virus[J].Res Vet Sci,2008,85(3):589-594.
[5]LAWRENCE SA.Beta-propiolactone:viral inactivation in vaccines and plasma products[J].PDA Journal of Pharmaceutical Science and Technology,2000,54(3):209-217.
[6]张标,佟琳,易山,等.甲醛和β-丙内酯灭活轮状病毒的效果[J].四川医学,2013,34(7):896-897.ZHANG Biao,TONG Lin.YI Shan,et al.Inactivation of rotavirus with formaldehyde andβ-propiolactone[J].Sichuan Medical Journal,2013,34(7):896-897.
[7]姜立民,林晓波,高磊,等.鹰-丙内酯对狂犬病病毒的灭活效果[J].国际流行病学传染病学杂志,2014,41(2):137-139.JIANG Limin,LIN Xiaobo,GAO Lei,et al.Inactivation of rabies virus withβ-propiolactone[J].International Journal of Epidemiology and Infectious Disea se,2014,41(2):137-139.
[8]蒋建江,戚凤春,胡艳灵,等.β-丙内酯对甲型肝炎病毒的灭活效应[J].中国生物制品学杂志,2012,25(5):529-530.JIANG Jianjiang,QI Fengchun,HU Yanling,et al.Inactivation of hepatitis A virus withβ-propiolactone[J].Chinese Journal of Biologicals,2012,25(5):529-530.
[9]张松乐,马丽娟,田光,等.SARS-CoV的培养和灭活条件的研究[J].中华实验和临床病毒学杂志,2005,19(2):135-137+202.ZHANG Songle,MA Lijuan,TIAN Guang,et al.Conditions for SARS-CoV cultivation and inactivation[J].Chinese Journal of Experimental and Clinical Virology,2005,19(2):135-137+202.
[10]ABD-ELGHAFFAR AA,ALI AE,BOSEILA AA,et al.Inactivation of rabies virus by hydrogen peroxide[J].Vaccine,2016,34(6):798-802.
[11]曹绘.鸡新城疫和禽流感(H9亚型)二联灭活疫苗灭活剂及佐剂的优化[D].杭州:浙江大学,2016.
[12]王白燕.二乙烯亚胺对脊髓灰质炎病毒Sabin株灭活效果以及灭活疫苗添加佐剂的效果观察[D].北京:中国协和医科大学,2010.The study of BEI inactivation effect on poliovirus Sabin strain and effect of adjuvant on inactivated vaccine[D].Beijing:Peking Union Medical College,2010.
[13]李朋.日本脑炎病毒样颗粒疫苗及双氯水灭活疫苗的探讨性研究[D].南京:南京农业大学,2013.Preliminary research on viral like particle vaccine and hydrogen peroxide inactivated va ccine of Japanese encephalitis[D].Nanjing:Nanjing Agricultural University,2013.
[14]李军英,张家友,杨晓明.生物制品中常用灭活剂的研究进展[J].中国生物制品学杂志,2018,31(9):1040-1043.LI Junying,ZHANG Jiayou,YANG Xiaoming.Progress in research on commonly used inactivators of biological products[J].Chinese Journal of Biologicals,2018,31(9):1040-1043.
[15]白玉,李敏,高恩明.病毒灭活疫苗生产工艺要点[J].中国生物制品学杂志,2011,24(9):1116-1117.
[16]尹华静,王寅,吴爽,等.新型冠状病毒预防性疫苗非临床研究评价的考虑[J].中国生物制品学杂志,2020,33(4):486-488.
[17]刘建东,张静飞,徐颖之,等.已上市人用预防疫苗佐剂的研究进展[J].中国生物制品学杂志,2020,33(4):455-460.LIU Jiandong,ZHANG Jingfei,XU Yingzhi,et al.Progress in research on licensed adjuvant for prophylactic vaccine for human use[J].Chinese Journal of Biologicals,2020,33(4):455-460.
[18]THANH LE T,ANDREADAKIS Z,KUMAR A,et al.The COVID-19 vaccine development landscape[J].Nature Reviews Drug Discovery,2020,19(5):305-306.
[19]YASU KO T-Y.Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen[J].Methods in Molecular Biology,2008,454:119-126.
[20]DARNELL ME,PLANT EP,WATANABE H,et al.Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets[J].The Journal of Infectious Diseases,2007,196(9):1329-1338.
[21]ZHOU J,WANG W,ZHONG Q,et al.Immunogenicity,safety,and protective efficacy of an inactivated SARSassociated coronavirus vaccine in rhesus monkeys[J].Vaccine,2004,23(24):3202-3209.
[22]LIN JT,ZHANG JS,SU N,et al.Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine[J].Antiviral Therapy,2007,12(7):1107-1113.
[23]TSENG CT,SBRANA E,IWATA-YOSHIKAWA N,et al.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J].PLoS One,2012,7(4):e35421.
[24]RAJ SV,MOU H,SMITS LS,et al.Dipeptidyl peptidase4 is a functional receptor for the emerging human coronavirus-EMC[J].Nature:International Weekly Journal of Science,2013,495(7440):251-254.
[25]WALLS AC,PARK YJ,TORTORICI MA,et al.Structure,function,and antigenicity of the SARS-CoV-2 spike glycoprotein[J].Cell,2020,181(2):281-292.
[26]AGRAWAL AS,TAO X,ALGAISSI A,et al.Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J].Human Vaccines&Immunotherapeutics,2016,12(9):2351-2356.
[27]WHO.Draft landscape of COVID 19 candidate vaccines[EB/OL].(2020-06-18)[2020-06-20].https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccine.
[28]武汉生物制品研究所有限责任公司.新型冠状病毒灭活疫苗(Vero细胞)随机、双盲、安慰剂平行对照Ⅰ/Ⅱ期临床试验[EB/OL].(2020-04-13)[2020-05-29].http://www.chictr.o rg.cn/showproj.aspx?proj=52227.
[29]中国生物.重磅!中国生物新冠灭活疫苗Ⅰ/Ⅱ期临床研究揭盲[EB/OL].(2020-06-16)[2020-06-21].https://mp.weixin.qq.com/s/X3qfTaCx9w9v9XyHB-EDAw.
[30]中国生物.全球首个新冠灭活疫苗国际临床(Ⅲ期)试验正式启动[EB/OL].(2020-06-23)[2020-6-24].https://mp.weixin.qq.com/s/02BhiuoAhFypxHFt3dNR2w.
[31]Sinovac.Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 Infection(COVID-19)[EB/OL].(2020-04-20)[2020-05-29].https://clinicaltrials.gov/ct2/show/NCT04352608?cond=COVID+v accine&draw=2.
[32]Sinovac.Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 Infection(COVID-19)[EB/OL].(2020-05-12)[2020-06-08].https://clinicaltrials.gov/ct2/show/NCT04383574.
[33]疫苗之益.科兴中维新型冠状病毒灭活疫苗Ⅰ/Ⅱ期临床研究揭盲,初步结果显示该疫苗具有良好的安全性和免疫原性[EB/OL].(2020-06-14)[2020-6-21].https://mp.weixin.qq.com/s/ck6HAHgzdOKfz6npzeleTw.
[34]WANG H,ZHANG YT,HUANG BY,et al.Development of an inactivated vaccine candidate,BBIBP-CorV,withpotent protection against SARS-CoV-2[J].Cell,2020,182(3):713-721+729.
[35]北京生物制品研究所有限责任公司.新型冠状病毒(2019-CoV)灭活疫苗(Vero细胞)Ⅰ/Ⅱ期临床试验[EB/OL].(2020-04-29)[2020-05-29].http://www.chictr.org.cn/showproj.aspx?proj=53003.
[36]Chinese Academy of Medical Sciences.Safety and immunogenicity study of an inactivated SARS-CoV-2vaccine for preventing against COVID-19[EB/0L].(2020-06-02)[2020-06-08].https://clinicaltrials.gov/ct2/show/NCT04412538.
[37]WANG XL,GUO XH,XIN QQ,et al.Neutralizing antibodies responses to SARS-CoV-2 in COVID-19inpatients and convalescent patients[J].Clinical Infectious Diseases,2020,ciaa721.
[38]CHANG SC,WANG JT,HUANG LM,et al.Longitudinal analysis of severe acute respiratory syndrome(SARS)coronavirus-specific antibody in SARS patients[J].Clin Diagn Lab Immunol,2005,12(12):1455-1457.
[39]DELRUE I,VERZELE D,MADDER A,et al.Inactivated virus vaccines from chemistry to prophylaxis:merits,risks and challenges[J].Expert Review of Vaccines,2012,11(6):695-719.
[40]BROWN F.Review of accidents caused by incomplete inactivation of viruses[J].Developments in Biological Standardization,1993,81:103-107.
[41]DARNELL MER,SUBBARAO K,FEINSTONE SM,et al.Inactivation of the coronavirus that induces severe acute respiratory syndrome,SARS-CoV[J].Journal of Virological Methods,2004,121(1):85-91.
[42]袁伟壮,杨逸成,刘旭玲,等.抗体依赖增强效应发生机制研究进展[J].中国人兽共患病学报,2017,33(7):650-657.YUAN Weizhuang,YANG Yicheng,LIU Xuling,et al.Research progress on mechanism of antibody-dependent enhancement[J].Chinese Journal of Zoonoses,2017,33(7):650-657.
[43]SMATTI MK,AL THANI AA,YASSINE HM.Viralinduced enhanced disease illness[J].Frontiers in Microbiology,2018,9:2991.
[44]WANG SF,TSENG SP,YEN CH,et al.Antibodydependent SARS coronavirus infection is mediated by antibodies against spike proteins[J].Biochemical and214.
[45]Graham BS.Rapid COVID-19 vaccine development[J].Science,2020,368(6494):945-946.
[46]MURALIDHARAN A,LI CG,WANG LS,et al.Immunopathogenesis associated with formaldehydeinactivated RSV vaccine in preclinical and clinical studies[J].Expert Review of Vaccines,2017,16(4):351-360.
[47]POLACK FP.Atypical measles and enhanced respiratory syncytial virus disease(ERD)made simple[J].Pediatric Research,2007,62(1):111-115.
[48]LIU J,LI S,LIU J,et al.Longitudinal characteristics of lymphocyte responses and cytokine pBiophysical Research Communications,2014,451(2):208-rofiles in the peripheral blood of SARS-CoV-2 infected patients[J].EBioMedicine,2020,55:102763.
[49]中国电子.世界首个!中国电子建造完成全球最大新冠疫苗生产车间[EB/OL].(2020-05-12)[2020-05-29].https://www.cec.com.cn/jtxw/2020/0513/8ac085cc713b441b01720b67b5e e019a.html.
基本信息:
DOI：10.19914/j.cjvi.2020.05.023
中图分类号:R392
引用信息:
[1]孟彤彤,孔庆福,王富珍,等.新型冠状病毒灭活疫苗研究进展[J].中国疫苗和免疫,2020,26(05):590-596.DOI:10.19914/j.cjvi.2020.05.023.
基金信息:
国家科技重大专项“疫苗临床评价技术平台建设”课题(2018ZX09734004)